Showing results (1-10 of 69) with videos related to
Sort By:
Pageof 7
Seminars in Oncology|January 8, 2017
Multiple myeloma epidemiology and survival: A unique malignancyDickran KazandjianClinical Advances in Hematology & Oncology : H&O|November 16, 2019
Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime timeDickran Kazandjian, Ola LandgrenSeminars in Oncology|January 8, 2017
A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survivalDickran Kazandjian, Ola LandgrenSeminars in Hematology|March 21, 2026
MRD as an early endpoint in myeloma and other hematologic malignancies: Implication for ongoing and future study designsElizabeth Hill, Dickran KazandjianBlood Cancer Discovery|September 1, 2023
MRD and Plasma Cell Dynamics after CAR T-cell Therapy in MyelomaOla Landgren, Dickran KazandjianSeminars in Hematology|February 24, 2026
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical managementOla Landgren, Rafat Abonour, Dickran KazandjianBest Practice & Research. Clinical Haematology|March 7, 2020
The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!Dickran Kazandjian, Alexander Dew, Elizabeth HillLeukemia & Lymphoma|September 5, 2022
T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscapeDickran Kazandjian, Andrew Kowalski, Ola LandgrenSeminars in Oncology|January 8, 2022
Current and prospective antibody-based therapies in multiple myelomaEmily Bryer, Christin DeStefano, Dickran KazandjianSeminars in Oncology|February 21, 2022
Daratumumab: A review of current indications and future directionsElizabeth Hill, Candis Morrison, Dickran KazandjianPageof 7